Laborjournal6d ago

#Biobusiness
„Wir bringen mit unserem Ballaststoff gleichzeitig Süße, Textur und Volumen in Lebensmittel ein – genau wie Zucker“.

Das bonner Transferprojekt Sweethoven Biotech entwickelt einen Ballaststoff, der die Süße von Zucker mit den gesundheitsfördernden Eigenschaften von Präbiotika vereint. Welche Etappen die angehenden Jungunternehmer bereits gemeistert haben, lest ihr hier: https://www.laborjournal.de/editorials/3451.php

#Laborjournal #LifeSci
#Süßungsmittel #Biotech #Mikrobiologie #Innovation #Fortschritt

LaborjournalMar 2

#Biobusiness
Hoffnung für die #Verbrennungsmedizin: Das künstliche #Hauttransplantat #denovoSkin des Zürcher Start-ups #Cutiss könnte ein Wendepunkt für die #RekonstruktiveChirurgie sein.

Es ahmt die Eigenschaften menschlicher Haut realistisch nach und kann in nur vier Wochen hergestellt werden. Aktuell läuft eine Phase-3-Studie.

Mehr dazu im Artikel von Carolin Sage: https://www.laborjournal.de/editorials/3442.php

#Laborjournal #LifeSci #Hautgewebetherapie #BioTec #Medizin #Fortschritt #Innovation

Yonhap Infomax NewsFeb 19
Samsung C&T Corp. will invest up to 9.4 trillion won ($7.1 billion) over three years in energy and bio sectors, while raising its minimum dividend per share by 25% to 2,500 won, as part of a strategy to drive growth and enhance shareholder returns.
#YonhapInfomax #SamsungCT #Investment #EnergySector #BioBusiness #DividendPolicy #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=105840
Samsung C&T to Invest up to 9.4 Trillion Won Over Three Years in Energy and Bio Sectors

Samsung C&T Corp. will invest up to 9.4 trillion won ($7.1 billion) over three years in energy and bio sectors, while raising its minimum dividend per share by 25% to 2,500 won, as part of a strategy to drive growth and enhance shareholder returns.

Yonhap Infomax
Yonhap Infomax NewsFeb 9
CJ CheilJedang reported a 21.6% drop in Q4 operating profit due to weak domestic food and bio segments, but results beat market expectations as overseas food sales hit a record high.
#YonhapInfomax #CJCheilJedang #OperatingProfit #Q4Results #BioBusiness #OverseasFoodSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=104599
Yonhap Infomax NewsFeb 9
CJ CheilJedang is projected to report a 26% drop in Q4 operating profit, as both its food and bio divisions faced weak demand and increased competition, with analysts citing intensified processed food rivalry and a surge in Chinese bio supply as key factors.
#YonhapInfomax #CJCheilJedang #OperatingProfit #FoodBusiness #BioBusiness #Q4Earnings #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=104459
CJ CheilJedang Forecasts 26% Drop in Q4 Operating Profit – Weakness in Food and Bio Divisions

CJ CheilJedang is projected to report a 26% drop in Q4 operating profit, as both its food and bio divisions faced weak demand and increased competition, with analysts citing intensified processed food rivalry and a surge in Chinese bio supply as key factors.

Yonhap Infomax
LaborjournalFeb 2

#Biobusiness
Das Start-up #Ymolution entwickelt synthetische Nano-Antikörper mittels Sporen-Oberflächen-Display. Damit umgehen die Gründer nicht nur Schwächen herkömmlicher Hybridom- oder Phagenverfahren, sondern schaffen auch eine neue Dimension funktionaler Vielfalt sowie eine deutlich reduzierte Produktionszeit. Was das mit Alpakas zu tun hat? - Im Artikel von Tobias Ludwig: https://www.laborjournal.de/editorials/3421.php

#Laborjournal #LifeSciences #OpenScience #AntibodyEngineering #Vegan #LabLife #Greifswald

LaborjournalJan 19

#Biobusiness
Innovativ, aber nicht überzeugend: Die EMA hat 2025 Wirkstoffe Jelrix (#Knorpelzelltherapie) und und #Alzheimermedikament Blarcamesin abgelehnt. Warum Sicherheit allein nicht reicht, welche Hürden im Weg standen und weshalb Neubewertungen Hoffnung machen, erfahren Sie im Artikel von Kathleen Gransalke:
https://www.laborjournal.de/editorials/3412.php

#Laborjournal #LifeSciences #EMA #Zulassung #KlinischeStudien #Alzheimer #Knorpelzelltherapie #RegenerativeMedizin #Pharmazie

Yonhap Infomax NewsDec 21
Samsung Group delivered record-breaking results in 2025, led by a semiconductor rebound and AI-driven growth, while resolving key legal risks and expanding its bio business, but faced ongoing challenges from industrial accidents and technology leaks.
#YonhapInfomax #SamsungGroup #Semiconductors #AI #BioBusiness #LegalRisksResolved #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=96532
[2025 Seven Major Groups Wrap-Up②] Samsung Marks Year of Semiconductor Rebound—Leads AI Power Race

Samsung Group delivered record-breaking results in 2025, led by a semiconductor rebound and AI-driven growth, while resolving key legal risks and expanding its bio business, but faced ongoing challenges from industrial accidents and technology leaks.

Yonhap Infomax
Yonhap Infomax NewsNov 26
Lotte Group has replaced 20 affiliate CEOs in a sweeping executive reshuffle, appointing Shin Yu-yeol as co-CEO of its bio unit and strengthening independent management by abolishing the HQ system.
#YonhapInfomax #LotteGroup #ExecutiveReshuffle #ShinYuYeol #BioBusiness #IndependentManagement #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=92590
'Lotte Executes Sweeping Overhaul, Replaces 20 Affiliate CEOs—Shin Yu-yeol Appointed Co-CEO of Bio Unit'

Lotte Group has replaced 20 affiliate CEOs in a sweeping executive reshuffle, appointing Shin Yu-yeol as co-CEO of its bio unit and strengthening independent management by abolishing the HQ system.

Yonhap Infomax
Yonhap Infomax NewsNov 11
CJ CheilJedang reported a 16.7% drop in Q3 operating profit, missing market expectations as bio and Feed & Care segments weakened, despite overseas food sales growth.
#YonhapInfomax #CJCheilJedang #OperatingProfit #BioBusiness #FeedAndCare #Q3Results #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=90171
CJ CheilJedang Q3 Operating Profit Falls 16.7%—Bio and Feed & Care Units Weigh on Results (Comprehensive)

CJ CheilJedang reported a 16.7% drop in Q3 operating profit, missing market expectations as bio and Feed & Care segments weakened, despite overseas food sales growth.

Yonhap Infomax